The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Stock and Other Ownership Interests - Asylia Therapeutics, Inc.
Honoraria - Abbvie; Adaptive Biotechnologies; Asylia Therapeutics, Inc.; BioTheryX; Bristol-Myers Squibb; DEM BioPharma; Karyopharm Therapeutics; Lytica Therapeutics; Meridian Therapeutics; Monte Rosa Therapeutics; Myeloma 360; Nanjing; Neoleukin Coroporation; Oncopeptides; Pfizer; Regeneron; Sanofi; Sporos Bioventures; Takeda
Consulting or Advisory Role - Abbvie; Adaptive Biotechnologies; Asylia Therapeutics, Inc.; BioTheryX; Bristol-Myers Squibb; DEM BioPharma; Karyopharm Therapeutics; Lytica Therapeutics; Meridian Therapeutics; Monte Rosa Therapeutics; Myeloma 360; Nanjing; Neoleukin Therapeutics; Oncopeptides; Pfizer; Regeneron; Sanofi; Sporos Bioventures; Takeda
Research Funding - Asylia Therapeutics, Inc.; BioTheryX; Bristol-Myers Squibb; CARsgen Therapeutics; Exelixis; Heidelberg Pharma; Heidelberg Pharma; Janssen; Sanofi; Takeda
Patents, Royalties, Other Intellectual Property - Asylia Therapeutics, Inc.
Impact of renal impairment (RI) on pharmacokinetics (PK) and clinical outcomes with mezigdomide plus dexamethasone (DEX) in relapsed/refractory multiple myeloma (RRMM).
 
Suzanne Trudel
Honoraria - Amgen; Forus; GlaxoSmithKline; Janssen; Pfizer; Sanofi
Consulting or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Roche
Research Funding - Amgen; Bristol-Myers Squibb; Genentech; GlaxoSmithKline; Janssen; K36 Therapeutics; Pfizer; Roche
 
Nizar J. Bahlis
Honoraria - Abbvie; Amgen; Celgene; Genentech/Roche; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Sanofi; Takeda
Consulting or Advisory Role - Amgen; Celgene; Janssen; Karyopharm Therapeutics; Pfizer; Sanofi; Takeda
Research Funding - Celgene (Inst); Janssen (Inst); Pfizer (Inst)
 
Rakesh Popat
Honoraria - Bristol-Myers Squibb/Celgene
Consulting or Advisory Role - Celgene; Galapagos NV; GlaxoSmithKline; Janssen; Roche
Speakers' Bureau - Abbvie; Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Johnson & Johnson/Janssen; Pfizer
Research Funding - GlaxoSmithKline (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline; Janssen
 
Maria-Victoria Mateos
Honoraria - Abbvie/Genentech; Amgen; Celgene; GlaxoSmithKline; Janssen-Cilag; Pfizer; Sanofi
Consulting or Advisory Role - Abbvie; Amgen; Celgene; GlaxoSmithKline; Janssen-Cilag; Kite, a Gilead company; Pfizer; Regeneron; Roche/Genentech; Stemline Therapeutics; Takeda
 
Annette J. Vangsted
Travel, Accommodations, Expenses - EHA; IMW
 
Karthik Ramasamy
Honoraria - Abbvie; Adaptive Biotechnologies; Amgen; Celgene/Bristol-Myers Squibb; EUSA Pharma; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Oncopeptides; Pfizer; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; Adaptive Biotechnologies; Amgen; Celgene/Bristol-Myers Squibb; EUSA Pharma; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Oncopeptides; Pfizer; Sanofi; Takeda
Research Funding - Amgen; Celgene/Bristol-Myers Squibb; GlaxoSmithKline; Janssen; Takeda
Travel, Accommodations, Expenses - Janssen; Menarini Group; Takeda
 
Joaquín Martínez-Lopez
Consulting or Advisory Role - Adaptive Therapeutics; Amgen; Astellas Amgen BioPharama; Bristol-Myers Squibb; Gilead Sciences; Janssen; Novartis; Pfizer
Speakers' Bureau - Adaptive Therapeutics; Amgen; Astellas Amgen BioPharama; Bristol-Myers Squibb; Gilead Sciences; Janssen; Novartis; Pfizer
Research Funding - Amgen; Astellas Amgen BioPharama; Bristol-Myers Squibb; Pfizer
Travel, Accommodations, Expenses - Amgen; Gilead Sciences; Janssen; Pfizer
 
Hang Quach
No Relationships to Disclose
 
Robert Z Orlowski
No Relationships to Disclose
 
Joseph Burnett
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Allison Gaudy
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Wencong Chen
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Jing Gong
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Joseph T. Hadala
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Cynthia Donahue
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Phillip Koo
Employment - Alexion Pharmaceuticals (I); Bristol-Myers Squibb
Stock and Other Ownership Interests - Alexion Pharmaceuticals (I); Bristol-Myers Squibb; Novartis
 
Yue Zhu
Employment - Bristol Myers Squibb Foundation
 
Jessica Katz
Employment - Bristol-Myers Squibb; NYU Bellevue Hospital; Temple University Hospital
Stock and Other Ownership Interests - Bristol-Myers Squibb; Variable Mutual Funds
 
Paul G. Richardson
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Karyopharm Therapeutics; Oncopeptides; Sanofi
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Karyopharm Therapeutics (Inst); Oncopeptides (Inst); Takeda (Inst)